| Not Yet Recruiting | User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking NCT07338513 | Tan Tock Seng Hospital | — |
| Not Yet Recruiting | Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD NCT07178249 | Guangzhou Jiayin Biotech Ltd | Phase 1 / Phase 2 |
| Completed | Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops NCT06969001 | SCAI Therapeutics | Phase 1 |
| Completed | CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Furthe NCT07255885 | Tan Tock Seng Hospital | — |
| Not Yet Recruiting | To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovasc NCT06888492 | Guangzhou Jiayin Biotech Ltd | EARLY_Phase 1 |
| Recruiting | A Long-term Follow up Study of EXG102-031 in Participants With wAMD NCT06859515 | Guangzhou Jiayin Biotech Ltd | — |
| Active Not Recruiting | NT-101 Topical Ophthalmic Solution in Patients With Wet AMD NCT06704009 | NexThera Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Effica NCT06683742 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Effic NCT06668064 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Afliber NCT06556368 | Kodiak Sciences Inc | Phase 3 |
| Active Not Recruiting | Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients NCT06518512 | Tan Tock Seng Hospital | — |
| Recruiting | Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals NCT06875245 | Faculty Hospital Kralovske Vinohrady | Phase 4 |
| Unknown | Efficacy and Safety of RC28-E Versus Aflibercept NCT05727397 | RemeGen Co., Ltd. | Phase 3 |
| Unknown | This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With R NCT05480293 | Sinocelltech Ltd. | Phase 3 |
| Recruiting | Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) NCT06952452 | Parc de Salut Mar | Phase 3 |
| Completed | Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) NCT05381948 | EyePoint Pharmaceuticals, Inc. | Phase 2 |
| Active Not Recruiting | Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD NCT04932980 | Berner Augenklinik | N/A |
| Withdrawn | Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration NCT04919096 | Clover Biopharmaceuticals AUS Pty | Phase 1 |
| Completed | A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) NCT07389577 | Jecho Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD NCT05407636 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in NCT04964089 | Kodiak Sciences Inc | Phase 3 |
| Completed | Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD NCT04884399 | Shanghai Biomabs Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD NCT05297292 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 / Phase 3 |
| Completed | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) NCT04832724 | AbbVie | Phase 2 |
| Completed | First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macu NCT04747197 | EyePoint Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One NCT04704921 | AbbVie | Phase 2 / Phase 3 |
| Active Not Recruiting | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] NCT04645212 | Adverum Biotechnologies, Inc. | — |
| Completed | Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers NCT04685369 | Brugmann University Hospital | — |
| Unknown | The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) NCT04564937 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Recruiting | MMP-9 Inhibition for Recalcitrant Wet AMD NCT04504123 | University of Iowa | Phase 2 |
| Terminated | A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration NCT04594681 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | Clinical Study on the Efficacy and Safety of BAT5906 Injection NCT05141994 | Bio-Thera Solutions | Phase 2 |
| Completed | A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) NCT04480463 | Sam Chun Dang Pharm. Co. Ltd. | Phase 3 |
| Completed | Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration NCT04270669 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) NCT05345236 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Treat and Extend Analysis Trial With Aflibercept in Wet-AMD NCT04113538 | Michel Giunta | Phase 3 |
| Completed | Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Nev NCT03939767 | Bayer | — |
| Completed | Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-A NCT03290794 | Bayer | — |
| Terminated | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokineti NCT03790852 | Kodiak Sciences Inc | Phase 1 |
| Completed | ADVM-022 Intravitreal Gene Therapy for Wet AMD NCT03748784 | Adverum Biotechnologies, Inc. | Phase 1 |
| Unknown | The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD) NCT04468997 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Completed | AAVCAGsCD59 for the Treatment of Wet AMD NCT03585556 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Deg NCT03558074 | Alkahest, Inc. | Phase 2 |
| Completed | Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degenerati NCT03558061 | Alkahest, Inc. | Phase 2 |
| Completed | Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet A NCT03312283 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Trea NCT03382587 | Bayer | — |
| Completed | Ziv-aflibercept Efficacy in Better Regulating AMD NCT03423823 | Kapil Kapoor | Phase 2 |
| Completed | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial NCT03066258 | REGENXBIO Inc. | Phase 1 / Phase 2 |
| Completed | Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranib NCT02257632 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients NCT01986907 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Trea NCT02005133 | Novartis Pharmaceuticals | — |
| Completed | Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study NCT01899963 | McMaster University | — |
| Completed | Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration NCT01914380 | Bayer | — |
| Withdrawn | Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients NCT01339949 | Oraya Therapeutics, Inc. | N/A |
| Completed | Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting NCT01318941 | Novartis Pharmaceuticals | — |
| Terminated | Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration NCT01086761 | Allergan | Phase 1 |
| Terminated | A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple In NCT01025232 | David M. Brown, M.D. | Phase 1 / Phase 2 |
| Completed | INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD NCT01016873 | Oraya Therapeutics, Inc. | Phase 2 |
| Unknown | Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Seconda NCT01217762 | Oraya Therapeutics, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD Tha NCT00679445 | NeoVista | Phase 2 |
| Completed | Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degenera NCT00503022 | Novartis | Phase 1 |
| Completed | Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Re NCT00138632 | Novartis | Phase 1 / Phase 2 |
| Terminated | A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Dege NCT00139282 | Genaera Corporation | Phase 3 |
| Withdrawn | Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macula NCT02036723 | Biocad | Phase 3 |